Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNMD CONMED	$55.38 -1.2%	$55.56	$46.00 ▼ $78.58	$1.73B	1.19	447,650 shs	332,606 shs
ENOV Enovis	$31.61 -2.3%	$34.73	$29.32 ▼ $51.00	$1.81B	1.79	786,005 shs	692,977 shs
LMAT LeMaitre Vascular	$81.40 +2.9%	$84.26	$71.42 ▼ $109.58	$1.84B	0.86	166,624 shs	205,755 shs
WEDXF Westaim	$22.59 -0.9%	$22.25	$16.62 ▼ $25.98	$482.57M	0.24	7,807 shs	1,335 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNMD CONMED	-1.34%	-8.05%	+11.31%	-9.20%	-26.13%
ENOV Enovis	-2.30%	-12.44%	-6.53%	-26.08%	-38.07%
LMAT LeMaitre Vascular	+2.88%	-3.98%	-9.09%	-18.29%	+1.72%
WEDXF Westaim	0.00%	-1.78%	-0.04%	+2.22%	+628.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNMD CONMED	4.4946 of 5 stars	2.2	3.0	2.5	4.3	2.8	0.8	3.1
ENOV Enovis	3.2555 of 5 stars	3.4	2.0	0.0	0.0	4.2	1.7	1.9
LMAT LeMaitre Vascular	2.5718 of 5 stars	2.3	2.0	3.3	0.0	1.9	2.5	1.3
WEDXF Westaim	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNMD CONMED	2.40	Hold	$62.20	12.32% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	83.48% Upside
LMAT LeMaitre Vascular	2.63	Moderate Buy	$98.14	20.57% Upside
WEDXF Westaim	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest WEDXF, ENOV, LMAT, and CNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/1/2025	CNMD CONMED	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$70.00 ➝ $58.00
5/1/2025	CNMD CONMED	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $57.00
5/1/2025	CNMD CONMED	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$91.00 ➝ $61.00
4/28/2025	CNMD CONMED	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $55.00
4/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
4/2/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
2/28/2025	LMAT LeMaitre Vascular	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $110.00
2/28/2025	LMAT LeMaitre Vascular	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNMD CONMED	$1.32B	1.30	$6.07 per share	9.13	$31.15 per share	1.78
ENOV Enovis	$2.15B	0.84	$4.61 per share	6.86	$62.66 per share	0.50
LMAT LeMaitre Vascular	$226.26M	8.13	$1.44 per share	56.52	$13.38 per share	6.08
WEDXF Westaim	$8.63M	55.92	$8.59 per share	2.63	$23.72 per share	0.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNMD CONMED	$132.42M	$3.80	13.06	10.92	1.83	10.13%	14.31%	5.64%	7/30/2025 (Estimated)
ENOV Enovis	-$33.26M	-$13.95	N/A	9.91	N/A	-5.95%	4.39%	2.80%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$30.10M	$1.98	44.48	37.51	2.22	19.40%	13.15%	11.47%	8/7/2025 (Estimated)
WEDXF Westaim	$183.98M	-$2.17	12.99	∞	N/A	284.74%	7.76%	7.29%	8/12/2025 (Estimated)

Latest WEDXF, ENOV, LMAT, and CNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	WEDXF Westaim	-$0.0316	-$0.34	-$0.3084	-$0.34	$1.34 million	($4.70) million
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/30/2025	Q1 2025	CNMD CONMED	$0.81	$0.95	+$0.14	$0.19	$313.38 million	$321.26 million
3/26/2025	Q4 2024	WEDXF Westaim	$0.0618	-$0.99	-$1.0518	-$0.99	$4.70 million	$4.60 million
2/27/2025	Q4 2024	LMAT LeMaitre Vascular	$0.49	$0.49	N/A	$0.49	$55.99 million	$55.81 million
2/26/2025	Q4 2024	ENOV Enovis	$0.92	$0.98	+$0.06	-$12.05	$555.14 million	$560.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNMD CONMED	$0.80	1.44%	N/A	21.05%	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.98%	+13.30%	40.40%	14 Years
WEDXF Westaim	$0.09	0.40%	N/A	N/A	N/A

Latest WEDXF, ENOV, LMAT, and CNMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/21/2025	CNMD CONMED	quarterly	$0.20	1.34%	6/13/2025	6/13/2025	7/3/2025
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025
2/24/2025	CNMD CONMED	quarterly	$0.20	1.29%	3/14/2025	3/14/2025	4/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNMD CONMED	0.94	2.30	1.06
ENOV Enovis	0.40	2.27	1.12
LMAT LeMaitre Vascular	N/A	7.74	5.52
WEDXF Westaim	N/A	11.81	11.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNMD CONMED	N/A
ENOV Enovis	98.45%
LMAT LeMaitre Vascular	84.64%
WEDXF Westaim	N/A

Insider Ownership

Company	Insider Ownership
CNMD CONMED	3.10%
ENOV Enovis	2.70%
LMAT LeMaitre Vascular	9.50%
WEDXF Westaim	4.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNMD CONMED	4,100	30.94 million	28.81 million	Optionable
ENOV Enovis	6,800	57.12 million	55.49 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
WEDXF Westaim	7	21.36 million	20.46 million	Not Optionable

WEDXF, ENOV, LMAT, and CNMD Headlines

Recent News About These Companies

The Westaim Corporation Reports Q1 2025 Results

May 14, 2025 | businesswire.com

Westaim (OTCMKTS:WEDXF) Trading 4.1% Higher - What's Next?

May 10, 2025 | marketbeat.com

Westaim (OTCMKTS:WEDXF) Trading Up 4.1% - Should You Buy?

May 10, 2025 | marketbeat.com

Short Interest in The Westaim Co. (OTCMKTS:WEDXF) Expands By 128.6%

April 30, 2025 | marketbeat.com

CC Capital and Westaim Complete Transaction, Creating Integrated Insurance and Asset Management Platform

April 3, 2025 | businesswire.com

Westaim Announces Receipt of Required Regulatory Approvals in Connection with CC Capital Transaction

March 27, 2025 | businesswire.com

The Westaim Corporation Announces Normal Course Issuer Bid

March 26, 2025 | businesswire.com

The Westaim Corporation Reports Q4 and Full Year 2024 Results and Update on Timing of Proposed Transactions with CC Capital

March 26, 2025 | businesswire.com

Westaim completes acquisition of ManhattanLife

February 6, 2025 | insurancebusinessmag.com

Westaim: Transforming Into A Potential Long-Term Compounding Machine

January 30, 2025 | seekingalpha.com

The Westaim Corp WEDXD

January 15, 2025 | morningstar.com

The Westaim Corporation Announces Completion of Arrangement

January 2, 2025 | businesswire.com

Westaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)

December 22, 2024 | theglobeandmail.com

The Westaim Corporation appoints CRO

December 6, 2024 | complianceweek.com

The Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials Online

November 27, 2024 | newsfilecorp.com

The Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials Online

November 27, 2024 | newsfilecorp.com

CC Capital & Westaim partner on new integrated insurance and asset management platform

October 11, 2024 | reinsurancene.ws

CC Capital and Westaim to create insurance and asset management platform

October 9, 2024 | pehub.com

Westaim Corporation: A Bargain In The Asset Management World

September 4, 2024 | seekingalpha.com

Westaim Corporation: Still Undervalued Based On NAV

July 19, 2024 | seekingalpha.com

The Westaim Corporation (WEDXF)

May 19, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?
By Chris Markoch | April 26, 2025
View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?

WEDXF, ENOV, LMAT, and CNMD Company Descriptions

CONMED NYSE:CNMD

$55.38 -0.68 (-1.22%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$55.39 +0.02 (+0.03%)

As of 05/23/2025 07:44 PM Eastern

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Enovis NYSE:ENOV

$31.61 -0.76 (-2.34%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$31.56 -0.06 (-0.18%)

As of 05/23/2025 07:52 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

LeMaitre Vascular NASDAQ:LMAT

$81.40 +2.28 (+2.88%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$81.47 +0.07 (+0.09%)

As of 05/23/2025 04:26 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Westaim OTCMKTS:WEDXF

$22.59 -0.20 (-0.88%)

As of 05/22/2025 03:59 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time